STRATA Skin Sciences (SSKN) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The annual meeting is scheduled for October 29, 2024, with voting on director elections and auditor ratification.
Shareholders of record as of September 19, 2024, are eligible to vote in person, by proxy card, phone, or internet.
The proxy statement details board structure, executive compensation, audit matters, and related party transactions.
Voting matters and shareholder proposals
Shareholders will vote to elect five directors and ratify Marcum LLP as the independent auditor for 2024.
Proposals require a plurality or majority, depending on the item, with specific rules for broker non-votes and abstentions.
Shareholder proposals for the 2025 meeting must be submitted between June 30 and July 31, 2025.
Board of directors and corporate governance
The board consists of five nominees, with a majority deemed independent under NASDAQ standards.
Committees include Audit and Compensation/Nominating & Governance, each with independent members.
The board met 12 times in the last fiscal year; all directors attended at least 75% of meetings.
Board diversity includes one female director and a range of professional backgrounds.
Latest events from STRATA Skin Sciences
- 2025 revenue fell 9% and net loss narrowed, but debt default and delisting raise going concern risks.SSKN
Q4 202526 Mar 2026 - Q2 revenue up 2% to $8.4M, gross margin at 58.5%, net loss narrows, and $2.1M raised post-quarter.SSKN
Q2 20241 Feb 2026 - Recurring revenue, margin gains, and expansion drive a turnaround with strong clinical support.SSKN
IAccess Alpha Buyside Best Ideas Virtual Fall Conference 202420 Jan 2026 - Dermatology device firm leverages recurring revenue, high margins, and exclusive market position.SSKN
Maxim Group’s 2024 Healthcare Virtual Summit19 Jan 2026 - Q3 2024 saw margin gains, DTC growth, and first non-GAAP operating profit since 2018.SSKN
Q3 202414 Jan 2026 - Registering up to $25M in flexible securities offerings to fund growth and product initiatives.SSKN
Registration Filing16 Dec 2025 - Registering up to $25M in flexible securities offerings to fund clinical, commercial, and strategic growth.SSKN
Registration Filing16 Dec 2025 - Q4 revenue up 10%, gross margin at 60.1%, and record international sales drive growth.SSKN
Q4 20241 Dec 2025 - Key votes include director elections, equity plan amendment, and auditor ratification.SSKN
Proxy Filing1 Dec 2025